ProfileGDS5678 / 1450479_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 95% 96% 97% 96% 95% 95% 97% 97% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.9476596
GSM967853U87-EV human glioblastoma xenograft - Control 28.928896
GSM967854U87-EV human glioblastoma xenograft - Control 38.9759396
GSM967855U87-EV human glioblastoma xenograft - Control 48.6836295
GSM967856U87-EV human glioblastoma xenograft - Control 58.9810396
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.9587797
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.6147996
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.4496495
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2757595
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.1036897
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.104697
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.0803396
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.0723196
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.972896